Best peptides for anti-aging.
The category with the largest claims, the longest timelines, and a measurement problem that no amount of enthusiasm resolves.
Ranked by published evidence · reviewed June 1, 2026
Anti-aging peptides face a structural obstacle that is worth stating before any individual compound: the outcome takes a lifetime to measure. A trial that demonstrated extended human healthspan would need to run for decades, which is why nothing in this category has evidence of the kind that would actually settle the question, and why it is unlikely to arrive soon.
In place of that evidence, the field runs on a chain of inference. A compound affects a pathway associated with aging in cells. The pathway is conserved in mice, where lifespan can be measured directly, and the compound extends it there. Therefore it should benefit humans. Every link is plausible, and mouse lifespan extension has a poor record of translating, so the conclusion is considerably weaker than the individual steps suggest.
A specific caution applies to a large subset of this category. Several of the best-known longevity peptides come from a single research group in Russia working on what they term peptide bioregulators. The literature is real, spans decades, and is internally consistent. It is also overwhelmingly produced by that one laboratory, published largely in Russian-language journals, and has not been independently replicated in Western randomized trials. Confidence should scale with independent replication, and here it has not happened.
The mitochondrial compounds sit on firmer ground. At least one has been through genuine clinical development for a defined rare mitochondrial disease rather than for aging in general, which is a meaningfully different proposition even when the mechanism is shared. A compound with a real trial program for a specific condition tells you something a compound marketed directly for longevity does not.
Interesting biology, unfalsifiable timelines, and an evidence base that leans heavily on animal lifespan work and single-group literature. Nothing here has demonstrated an anti-aging effect in humans.
Ranked by evidence.
Ordered by PepCue's evidence tier, not by claimed effect size. A compound with a larger reported result but less human data ranks below one that has actually been tested.
- 01SS-31C tier · 57/100In human trialselamipretide
SS-31, known generically as elamipretide and chemically as the tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2',6'-dimethyltyrosine), is a synthetic, cell-permeable, mitochondria-targeting peptide of the "Szeto-Schiller" (SS) aromatic-cationic class, originally discovered by Hazel Szeto and Peter Schiller at Cornell during opioid-peptide work.
Full profile and sources → - 02GlutathioneD tier · 45/100Research / preclinicalGSH · reduced glutathione
Glutathione (GSH) is a tripeptide of glutamate, cysteine, and glycine that serves as the body's principal intracellular antioxidant and a key cofactor in detoxification.
Full profile and sources → - 03GHK-CuD tier · 45/100Cosmetic / topicalcopper peptide
GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide with the sequence glycyl-L-histidyl-L-lysine.
Full profile and sources → - 04ThymalinD tier · 39/100Research / preclinicalthymus peptide extract
Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus gland, developed by Vladimir Khavinson's group in the Soviet Union and Russia.
Full profile and sources → - 05MOTS-cF tier · 30/100Research / preclinical
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015.
Full profile and sources → - 06HumaninF tier · 28/100Research / preclinical
Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome.
Full profile and sources → - 07EpitalonF tier · 22/100Research / preclinical
Epitalon (also spelled Epithalon or Epithalone; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide developed in the 1980s by the Russian gerontologist Vladimir Khavinson and colleagues at the St.
Full profile and sources → - 08VilonF tier · 15/100Research / preclinicalLys-Glu dipeptide
Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St.
Full profile and sources → - 09FOXO4-DRIF tier · 15/100Research / preclinical
FOXO4-DRI is a synthetic senolytic peptide derived from the transcription factor FOXO4 (Forkhead box O4).
Full profile and sources → - 105-Amino-1MQF tier · 15/100Research / preclinical
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, substrate-site inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT).
Full profile and sources → - 11PinealonF tier · 12/100Research / preclinical
Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR).
Full profile and sources →
FAQ.
Do any peptides actually slow aging?
None has demonstrated it in humans. The outcome requires decades to measure, so the evidence consists of cell pathway work, animal lifespan studies, and biomarker changes, none of which establish the claim.
What about biological age tests showing improvement?
Those tests measure correlates of aging such as methylation patterns. Shifting a correlate is not the same as changing the underlying trajectory, and no peptide has been shown to do the latter.
Why are the Russian bioregulator peptides treated cautiously here?
Not because the research is fabricated, but because it comes overwhelmingly from one group and has not been independently replicated in Western randomized trials. That is a real limitation on how much confidence the results support.
Cite this page
PepCue. “Best peptides for anti-aging: separating mechanism from evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/best-peptides-for/anti-aging.